Erin Parry, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, briefly outlines the current landscape of trials exploring the treatment of Richter’s transformation (RT). As RT has been historically difficult to treat with traditional therapies, Dr Parry hopes that clinical trial data looking into alternative therapies will inform the treatment of these patients over the coming years. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.